NATONI, ALESSANDRO
NATONI, ALESSANDRO
DIPARTIMENTO DI MEDICINA TRASLAZIONALE E DI PRECISIONE
A 13-Glycosylation Gene Signature in Multiple Myeloma Can Predicts Survival and Identifies Candidates for Targeted Therapy (GiMM13)
2016 Connolly, C; Jha, A; Natoni, A; O'Dwyer, Me
A cell culture system that mimics chronic lymphocytic leukemia cells microenvironment for drug screening and characterization
2013 Natoni, Alessandro; O'Dwyer, Michael; Santocanale, Corrado
A high through-put screen for small molecules modulating MCM2 phosphorylation identifies Ryuvidine as an inducer of the DNA damage response
2014 Fitzgerald, Jennifer; Murillo, Laura S; O'Brien, Gemma; O'Connell, Enda; O'Connor, Aisling; Wu, Kevin; Wang, Guan-Nan; Rainey, Michael D; Natoni, Alessandro; Healy, Sandra; O'Dwyer, Michael; Santocanale, Corrado
Calicivirus translation initiation requires an interaction between VPg and eIF 4 E
2005 Goodfellow, Ian; Chaudhry, Yasmin; Gioldasi, Ioanna; Gerondopoulos, Andreas; Natoni, Alessandro; Labrie, Louisette; Laliberté, Jean-François; Roberts, Lisa
CD38(low) Natural Killer Cells Transiently Expressing CD16(F158V) m-RNA Potentiates the Therapeutic Activity of Daratumumab Against Multiple Myeloma with Minimal Effector NK Cell Fratricide
2018 Sarkar, S; Chauhan, S; Stikvoort, A; Natoni, A; Daly, J; Henderson, R; Mutis, T; O'Dwyer, Me
Characterization of a Dual CDC7/CDK9 Inhibitor in Multiple Myeloma Cellular Models
2013 Natoni, Alessandro; Coyne, Mark R E; Jacobsen, Alan; Rainey, Michael D; O'Brien, Gemma; Healy, Sandra; Montagnoli, Alessia; Moll, Jürgen; O'Dwyer, Michael; Santocanale, Corrado
Chronic nitric oxide exposure induces prostate cell carcinogenesis, involving genetic instability and a pro-tumorigenic secretory phenotype
2022 Burke, Amy J; Mcauliffe, Jake D; Natoni, Alessandro; Ridge, Sarah; Sullivan, Francis J; Glynn, Sharon A
Combination targeting of sialylation and the proteasome inhibits tumor growth and increases survival in a humanized mouse multiple myeloma model
2018 Reagan, M.; Farrell, M.; Macauley, M.; Natoni, A.; Fairfield, H.; O’Dwyer, M.
Concurrent Inhibition of Pim and Akt Pathways with Pim447 and Afuresertib Activates FOXO3a and Depletes c-Myc to Induce Synergistic Cell Death in Multiple Myeloma
2015 Keane, N; Reidy, M; Natoni, A; O'Dwyer, M
Cybord-Dara in Newly Diagnosed Transplant-Eligible Multiple Myeloma: Follow up Results from the 16Bcni-001/Ctrial-IE 16-02 Study Show High Rates of MRD Negativity at End of Treatment
2021 Swan, D; O'Dwyer, Me; Cahill, M; Krawczyk, J; Mykytiv, V; Quinn, J; Henderson, R; Mcellistrim, C; Hernando, A; Parker, I; Nolan, M; Lenihan, E; Szegezdi, E; Naicker, Sd; Lynch, K; Natoni, A; Ryan, A; Murphy, P
CyBorD-DARA in Newly Diagnosed Transplant-Eligible Multiple Myeloma: Results from the 16-BCNI-001/CTRIAL-IE 16-02 Study Show High Rates of MRD Negativity at End of Treatment
2022 Swan, D; Henderson, R; Mcellistrim, C; Naicker, S D; Quinn, J; Cahill, M R; Mykytiv, V; Lenihan, E; Mulvaney, E; Nolan, M; Parker, I; Natoni, A; Lynch, K; Ryan, A E; Szegezdi, E; Krawczyk, J; Murphy, P; O'Dwyer, M
Cybord-Dara Is a Highly Effective Upfront Treatment for Newly Diagnosed Multiple Myeloma. Initial Efficacy Results of the 16-Bcni-001/Ctrial-IE (ICORG) 16-02 Study
2018 Henderson, Robert; Cahill, Mary R; Murphy, Philip; Mykytiv, Vitaliy; Quinn, John; Walsh, Jessica; Lenihan, Elizabeth; Kenny, Tara; Hernando, Andres; Hirakata, Grace; Parker, Imelda; Kinsella, Emma; Gannon, Grainne; Natoni, Alessandro; O'Dwyer, Michael E
CyBorD-DARA is potent initial induction for MM and enhances ADCP: initial results of the 16-BCNI-001/CTRIAL-IE 16-02 study
2019 O'Dwyer, M; Henderson, R; Naicker, S D; Cahill, M R; Murphy, P; Mykytiv, V; Quinn, J; Mcellistrim, C; Krawczyk, J; Walsh, J; Lenihan, E; Kenny, T; Hernando, A; Hirakata, G; Parker, I; Kinsella, E; Gannon, G; Natoni, A; Lynch, K; Ryan, A E
Cyclophosphamide alters the tumor cell secretome to potentiate the anti-myeloma activity of daratumumab through augmentation of macrophage-mediated antibody dependent cellular phagocytosis
2021 Naicker, Serika D; Feerick, Claire L; Lynch, Kevin; Swan, Dawn; Mcellistrim, Cian; Henderson, Robert; Leonard, Niamh A; Treacy, Oliver; Natoni, Alessandro; Rigalou, Athina; Cabral, Joana; Chiu, Christopher; Sasser, Kate; Ritter, Thomas; O'Dwyer, Michael; Ryan, Aideen E
Dual Cdc7/Cdk9 kinase inhibitor, PHA-767491, targets both quiescent and proliferating CLL cells
2010 Santocanale, A; Natoni, A; Murillo, L; Catherwood, M; Montagnoli, A; Samali, A; O'Dwyer, M
E-Selectin Ligand Expression Increases with Progression of Myeloma and Induces Drug Resistance in a Murine Transplant Model, Which Is Overcome By the Glycomimetic E-Selectin Antagonist, GMI-1271
2015 Natoni, Alessandro; Smith, Theodore A. G.; Keane, Niamh; Locatelli-Hoops, Silvia C.; Oliva, Isabela; Fogler, William E.; Magnani, John L.; O'Dwyer, Michael
E-selectin ligands recognised by HECA452 induce drug resistance in myeloma, which is overcome by the E-selectin antagonist, GMI-1271
2017 Natoni, A; Smith, T A G; Keane, N; Mcellistrim, C; Connolly, C; Jha, A; Andrulis, M; Ellert, E; Raab, M S; Glavey, S V; Kirkham-McCarthy, L; Kumar, S K; Locatelli-Hoops, S C; Oliva, I; Fogler, W E; Magnani, J L; O'Dwyer, M E
Early growth response-1 is a regulator of DR5-induced apoptosis in colon cancer cells
2010 Mahalingam, D; Natoni, A; Keane, M; Samali, A; Szegezdi, E
Engineering CD38 low natural killer cells to transiently express CD16 (f158v) m-RNA enhances the cytotoxic potential of daratumumab against multiple myeloma with minimal NK cell fratricide
2018 Sarkar, S.; Chauhan, S.; Natoni, A.; Daly, J.; Henderson, R.; O’Dwyer, M.
Enhancement of antitumor properties of rhTRAIL by affinity increase toward its death receptors
2009 Reis, Carlos R; van der Sloot, Almer M; Szegezdi, Eva; Natoni, Alessandro; Tur, Vicente; Cool, Robbert H; Samali, Afshin; Serrano, Luis; Quax, Wim J
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| A 13-Glycosylation Gene Signature in Multiple Myeloma Can Predicts Survival and Identifies Candidates for Targeted Therapy (GiMM13) | 2016 | Connolly, C; Jha, A; Natoni, A; O'Dwyer, Me | |
| A cell culture system that mimics chronic lymphocytic leukemia cells microenvironment for drug screening and characterization | 2013 | Natoni, Alessandro; O'Dwyer, Michael; Santocanale, Corrado | |
| A high through-put screen for small molecules modulating MCM2 phosphorylation identifies Ryuvidine as an inducer of the DNA damage response | 2014 | Fitzgerald, Jennifer; Murillo, Laura S; O'Brien, Gemma; O'Connell, Enda; O'Connor, Aisling; Wu, Kevin; Wang, Guan-Nan; Rainey, Michael D; Natoni, Alessandro; Healy, Sandra; O'Dwyer, Michael; Santocanale, Corrado | |
| Calicivirus translation initiation requires an interaction between VPg and eIF 4 E | 2005 | Goodfellow, Ian; Chaudhry, Yasmin; Gioldasi, Ioanna; Gerondopoulos, Andreas; Natoni, Alessandro; Labrie, Louisette; Laliberté, Jean-François; Roberts, Lisa | |
| CD38(low) Natural Killer Cells Transiently Expressing CD16(F158V) m-RNA Potentiates the Therapeutic Activity of Daratumumab Against Multiple Myeloma with Minimal Effector NK Cell Fratricide | 2018 | Sarkar, S; Chauhan, S; Stikvoort, A; Natoni, A; Daly, J; Henderson, R; Mutis, T; O'Dwyer, Me | |
| Characterization of a Dual CDC7/CDK9 Inhibitor in Multiple Myeloma Cellular Models | 2013 | Natoni, Alessandro; Coyne, Mark R E; Jacobsen, Alan; Rainey, Michael D; O'Brien, Gemma; Healy, Sandra; Montagnoli, Alessia; Moll, Jürgen; O'Dwyer, Michael; Santocanale, Corrado | |
| Chronic nitric oxide exposure induces prostate cell carcinogenesis, involving genetic instability and a pro-tumorigenic secretory phenotype | 2022 | Burke, Amy J; Mcauliffe, Jake D; Natoni, Alessandro; Ridge, Sarah; Sullivan, Francis J; Glynn, Sharon A | |
| Combination targeting of sialylation and the proteasome inhibits tumor growth and increases survival in a humanized mouse multiple myeloma model | 2018 | Reagan, M.; Farrell, M.; Macauley, M.; Natoni, A.; Fairfield, H.; O’Dwyer, M. | |
| Concurrent Inhibition of Pim and Akt Pathways with Pim447 and Afuresertib Activates FOXO3a and Depletes c-Myc to Induce Synergistic Cell Death in Multiple Myeloma | 2015 | Keane, N; Reidy, M; Natoni, A; O'Dwyer, M | |
| Cybord-Dara in Newly Diagnosed Transplant-Eligible Multiple Myeloma: Follow up Results from the 16Bcni-001/Ctrial-IE 16-02 Study Show High Rates of MRD Negativity at End of Treatment | 2021 | Swan, D; O'Dwyer, Me; Cahill, M; Krawczyk, J; Mykytiv, V; Quinn, J; Henderson, R; Mcellistrim, C; Hernando, A; Parker, I; Nolan, M; Lenihan, E; Szegezdi, E; Naicker, Sd; Lynch, K; Natoni, A; Ryan, A; Murphy, P | |
| CyBorD-DARA in Newly Diagnosed Transplant-Eligible Multiple Myeloma: Results from the 16-BCNI-001/CTRIAL-IE 16-02 Study Show High Rates of MRD Negativity at End of Treatment | 2022 | Swan, D; Henderson, R; Mcellistrim, C; Naicker, S D; Quinn, J; Cahill, M R; Mykytiv, V; Lenihan, E; Mulvaney, E; Nolan, M; Parker, I; Natoni, A; Lynch, K; Ryan, A E; Szegezdi, E; Krawczyk, J; Murphy, P; O'Dwyer, M | |
| Cybord-Dara Is a Highly Effective Upfront Treatment for Newly Diagnosed Multiple Myeloma. Initial Efficacy Results of the 16-Bcni-001/Ctrial-IE (ICORG) 16-02 Study | 2018 | Henderson, Robert; Cahill, Mary R; Murphy, Philip; Mykytiv, Vitaliy; Quinn, John; Walsh, Jessica; Lenihan, Elizabeth; Kenny, Tara; Hernando, Andres; Hirakata, Grace; Parker, Imelda; Kinsella, Emma; Gannon, Grainne; Natoni, Alessandro; O'Dwyer, Michael E | |
| CyBorD-DARA is potent initial induction for MM and enhances ADCP: initial results of the 16-BCNI-001/CTRIAL-IE 16-02 study | 2019 | O'Dwyer, M; Henderson, R; Naicker, S D; Cahill, M R; Murphy, P; Mykytiv, V; Quinn, J; Mcellistrim, C; Krawczyk, J; Walsh, J; Lenihan, E; Kenny, T; Hernando, A; Hirakata, G; Parker, I; Kinsella, E; Gannon, G; Natoni, A; Lynch, K; Ryan, A E | |
| Cyclophosphamide alters the tumor cell secretome to potentiate the anti-myeloma activity of daratumumab through augmentation of macrophage-mediated antibody dependent cellular phagocytosis | 2021 | Naicker, Serika D; Feerick, Claire L; Lynch, Kevin; Swan, Dawn; Mcellistrim, Cian; Henderson, Robert; Leonard, Niamh A; Treacy, Oliver; Natoni, Alessandro; Rigalou, Athina; Cabral, Joana; Chiu, Christopher; Sasser, Kate; Ritter, Thomas; O'Dwyer, Michael; Ryan, Aideen E | |
| Dual Cdc7/Cdk9 kinase inhibitor, PHA-767491, targets both quiescent and proliferating CLL cells | 2010 | Santocanale, A; Natoni, A; Murillo, L; Catherwood, M; Montagnoli, A; Samali, A; O'Dwyer, M | |
| E-Selectin Ligand Expression Increases with Progression of Myeloma and Induces Drug Resistance in a Murine Transplant Model, Which Is Overcome By the Glycomimetic E-Selectin Antagonist, GMI-1271 | 2015 | Natoni, Alessandro; Smith, Theodore A. G.; Keane, Niamh; Locatelli-Hoops, Silvia C.; Oliva, Isabela; Fogler, William E.; Magnani, John L.; O'Dwyer, Michael | |
| E-selectin ligands recognised by HECA452 induce drug resistance in myeloma, which is overcome by the E-selectin antagonist, GMI-1271 | 2017 | Natoni, A; Smith, T A G; Keane, N; Mcellistrim, C; Connolly, C; Jha, A; Andrulis, M; Ellert, E; Raab, M S; Glavey, S V; Kirkham-McCarthy, L; Kumar, S K; Locatelli-Hoops, S C; Oliva, I; Fogler, W E; Magnani, J L; O'Dwyer, M E | |
| Early growth response-1 is a regulator of DR5-induced apoptosis in colon cancer cells | 2010 | Mahalingam, D; Natoni, A; Keane, M; Samali, A; Szegezdi, E | |
| Engineering CD38 low natural killer cells to transiently express CD16 (f158v) m-RNA enhances the cytotoxic potential of daratumumab against multiple myeloma with minimal NK cell fratricide | 2018 | Sarkar, S.; Chauhan, S.; Natoni, A.; Daly, J.; Henderson, R.; O’Dwyer, M. | |
| Enhancement of antitumor properties of rhTRAIL by affinity increase toward its death receptors | 2009 | Reis, Carlos R; van der Sloot, Almer M; Szegezdi, Eva; Natoni, Alessandro; Tur, Vicente; Cool, Robbert H; Samali, Afshin; Serrano, Luis; Quax, Wim J |